A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
Public ClinicalTrials.gov record NCT05368285. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-finding Study to Assess the Efficacy and Safety of CDX-0159 in Patients With Chronic Spontaneous Urticaria
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Spontaneous Urticaria
Study identification
- NCT ID
- NCT05368285
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 208 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 19, 2022 (Actual)
- Primary completion
- Sep 28, 2023 (Actual)
- Completion
- Dec 20, 2024 (Actual)
- Last update posted
- Mar 26, 2025
2022 – 2024
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Research Center of Alabama dba Allervie Clinical Research | Birmingham | Alabama | 35249 | — |
| Medical Research of Arizona | Scottsdale | Arizona | 85251 | — |
| Little Rock Allergy & Asthma CRC | Little Rock | Arkansas | 72205 | — |
| Kern Research, Inc | Bakersfield | California | 93301 | — |
| Allergy & Asthma Consultants | Redwood City | California | 94063 | — |
| IMMUNOe Research Centers | Centennial | Colorado | 80112 | — |
| Treasure Valley Medical Research | Boise | Idaho | 83706 | — |
| Allergy & Asthma Specialists, PSC | Owensboro | Kentucky | 42301 | — |
| Institute for Asthma and Allergy | Chevy Chase | Maryland | 20815 | — |
| Chesapeake Clinical Research | White Marsh | Maryland | 21162 | — |
| Respiratory Medicine Research Institute of Michigan, PLC | Ypsilanti | Michigan | 48197 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Montefiore Medical Center/Subspeciality-Allergy and Immunology | The Bronx | New York | 10461 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05368285, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2025 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05368285 live on ClinicalTrials.gov.